

SUPPLEMENTARY MATERIAL

A Maximum Use Trial of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

Robert Bissonnette, MD, FRCPC,¹ Robert S. Call, MD,² Tooraj Raoof, MD,³ Zhaoyin Zhu, PhD,⁴ Swamy Yeleswaram, PhD,⁴ Xiaohua Gong, PhD,⁴ Mark Lee, MD⁵

¹Innovaderm Research, Montreal, QC, Canada; ²Clinical Research Partners, Richmond, VA, USA; ³Encino Research Center, Encino, CA, USA; ⁴Incyte Corporation, Wilmington, DE, USA; ⁵Progressive Clinical Research, San Antonio, TX, USA

American Journal of Clinical Dermatology

Corresponding author: Robert Bissonnette, MD (rbissonnette@innovaderm.com)

Contents

Table of Contents


Table S1. Platelet and Hemoglobin Levels in the 5 Patients With Highest C _{ss}	2
Figure S1. Mean Plasma Concentrations on Day 1 and Day 28 in the (A and D) Overall Population and by (B and E) Baseline BSA and (C and F) Age Groups	3
Figure S2. IGA Scores by Study Day	4
Figure S3. Change From Baseline in Daily Itch NRS Score	5
Figure S4. Proportion of Patients Achieving EASI-75	6
Figure S5. Representative Clinical Images	7

Table S1. Platelet and Hemoglobin Levels in the 5 Patients With Highest C_{ss}

Age, y/Sex	BSA Treated, %	C _{ss} , nM	Platelet Count on Day 28, 10 ⁹ /L		Hemoglobin on Day 28, g/L	
			Measured	Change From Baseline	Measured	Change From Baseline
45/M	25	111	307	9	135	-4
46/M	27	122	243	27	180	-2
13/M	43.4	269	345	81	164	10
32/F	45	711	449	137	130	-15
60/M	90	1870	173	-227	136	-18


BSA, body surface area; C_{ss}, steady-state plasma concentration.

Figure S1. Mean Plasma Concentrations on Day 1 and Day 28 in the (A and D) Overall Population and by (B and E) Baseline BSA and (C and F) Age Groups




Data are shown as semilog plots.
 Error bars represent standard error of the mean.
 BSA, body surface area.

Figure S2. IGA Scores by Study Day




IGA, Investigator's Global Assessment.

Figure S3. Change From Baseline in Daily Itch NRS Score



NRS, numerical rating scale.

Figure S4. Proportion of Patients Achieving EASI-75



EASI-75, $\geq 75\%$ improvement in Eczema Area and Severity Index.

Figure S5. Representative Clinical Images

